Genetic alterations in the human kidney clear cell carcinoma line Рпоч1-КК
https://doi.org/10.17650/2313-805X-2016-3-3-81-85
Abstract
Continuous cell line Рпоч1-КК from the сollection of N. N. Blokhin Russian Cancer Research Center refers to the kidney clear cell carcinoma subtypе. It is useful for study of carcinogenesis and molecular targets for targeted therapy.
Objective. Analysis of the genetic alterations in a stable cell culture Рпоч1-КК to characterize this model cell line.
Results. Alterations in VHL (exons 1, 2 and 3) and TP53 genes (exons 6–10) were identified by amplification of genomic DNA followed by fragment analysis polymerase chain reaction and direct Sanger sequencing. An extended deletion in exon 1 in combination with mutation in exon 7 of VHL gene and 2 polymorphisms in exon 4 of TP53 gene were reveated. Such simultaneous alterations in 2 suppressor genes maight be one of the causes of aggressive tumor growth and its resistance to standard therapy.
About the Authors
A. A. Lushnikova
N.N. Blokhin Russian Cancer Reseach Center, Ministry of Health of Russia; 24 Kashirskoe Shosse, Moscow, 115478, Russia
Russian Federation
Russian Federation
L. F. Morozova
N.N. Blokhin Russian Cancer Reseach Center, Ministry of Health of Russia; 24 Kashirskoe Shosse, Moscow, 115478, Russia
Russian Federation
Russian Federation
I. S. Abramov
V.A. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences; 3 Vavilova St., Moscow, 119991, Russia
Russian Federation
Russian Federation
T. S. Dubrovina
N.N. Blokhin Russian Cancer Reseach Center, Ministry of Health of Russia; 24 Kashirskoe Shosse, Moscow, 115478, Russia
Russian Federation
Russian Federation
A. V. Balbutskiy
N.N. Blokhin Russian Cancer Reseach Center, Ministry of Health of Russia; 24 Kashirskoe Shosse, Moscow, 115478, Russia
Russian Federation
Russian Federation
References
1. Давыдова М. И., Аксель Е. М. Статистика злокачественных новообразований в России и странах СНГ в 2012 году. М.: Издательская группа РОНЦ, 2014. 226 с. [Davydovа М. I., Аksel’ Е. М. Statistics of malignant tumors in Russia and CIS countries in 2012. Мoscow: Izdatel’skaya gruppa RONTS, 2014. 226 p. (In Russ.)].
2. Михайленко Д. С., Попов А. М., Курынин Р. В. и др. Анализ молекулярно- генетических нарушений в генах VHL, RASSF1, FHIT и TP53 при светлоклеточном раке почки. Медицинская генетика 2008;(4):9–14. [Мikhaylenkо D. S., Popov А. М., Kurynin R. V. et al. Аnalysis of molecular & genetic defects in VHL, RASSF1, FHIT and TP53 genes at the clear cell adenocarcinoma. Меditsinskaya genetika = Меdical Genetics 2008;(4):9–14. (In Russ.)]
3. Коллекция опухолевых штаммов человека. Под ред. М.И. Давыдова. М.: Практическая медицина, 2009. С. 37–38. [Collection of human tumor strains. Ed. Davydov М. I. Мoscow: Prakticheskaya meditsina, 2009. Pp. 37–38. (In Russ.)].
4. Lyubchenko L. N., Abramov I. S., Bateneva E. I. et al. DNA-diagnostics for inherited breast and/or ovarian cancer: standard approaches and novel technologies; Eur J Hum Gen 2014;22(1):243.
5. Михайленко Д. С. Анализ молекулярно-генетических нарушений, ассоциированных с развитием злокачественных новообразований почки. Автореф. дис. … канд. мед. наук. М., 2008. [Мikhaylenkо D. S. Аnalysis of molecular & genetic defects, associated with the development of malignant kidney tumors. Аuthor’s abstract of thesis … of candidate of medical sciences. Мoscow, 2008. (In Russ.)].
6. Михайленко Д. С., Григорьева М. В., Землякова В. В. и др. Молекулярно-генетические нарушения в гене VHL и метилирование некоторых генов-супрес соров в спорадических светлоклеточных карциномах почки. Онкоурология 2010;(2):32– 6. [Мikhaylenkо D. S., Grigor’evа М.V., Zemlyakovа V. V. et al. Моlecular & genetic defects in VHL gene and methylation of some suppressing genes in spo radic clear cell kidney carcinomas. Оnkourolo giya = Cancer Urology 2010;(2):32–6. (In Russ.)].
7. Leisz S., Schulz K., Erb S. et al. Distinct von Hippel-Lindau gene and hypoxiaregulated alterations in gene and protein expression pat terns of renal cell carcinoma and their effects om metabolism. Oncotarget 2015;6(13);11395–406.
8. Stehle F., Leisz S., Schulz K. et al. VHL-dependent alterations in the secretome of renal cell carcinoma: association with immune cell response. Oncotarget 2015;6(41):43420–37. PMID: 26486078.
9. Jung Y. S., Chun H. Y., Yoon M. H., Park B. J. Elevated estrogen receptor-α in VHL-deficient condition induces microtubule organizing center amplification via disruption of BRCA1/Rad51 interaction. Neoplasia 2014;16(12);1070–81. DOI: 10.1016/j.neo.2014.09.013.
10. Носов Д. А., Яковлева Е. С., Федянин М. Ю. и др. Прогностическое значение инактивирующих нарушений в гене VHL у больных метастатическим почечно- клеточным раком. Онкоурология 2011;(3):47–51. [Nosov D. А., Yakovlevа Е. S., Fedyanin М. Yu. et al. Prognostic value if desactivating defects in VHL gene at patients with metastatic renal cell carcinoma. Оnkourologiya = Cancer Urology 2011;(3):47–51. (In Russ.)].
11. Alexiev B. A., Drachenberg C. B. Clear cell papillary renal cell carcinoma: incidence, morphological features, immunohistochemi cal profile, and biologic behavior: a single institution study. Pathol Res Pract 2014;210(4); 234–41.
12. Yates L. R., Campbell P. J. Evolution of cancer genome. Nat Ren Genet 2012;13(11):795– 806.
Review
For citations:
Lushnikova A.A., Morozova L.F., Abramov I.S., Dubrovina T.S., Balbutskiy A.V. Genetic alterations in the human kidney clear cell carcinoma line Рпоч1-КК. Advances in Molecular Oncology. 2016;3(3):81-85. (In Russ.) https://doi.org/10.17650/2313-805X-2016-3-3-81-85
Views:
788
Email this article 